drugset
drugset / Trial / NCT02255513

A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD

NCT02255513 ↗

Phase 3 Completed 43 enrolled Ironshore Pharmaceuticals and Development, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will examine the efficacy and safety of HLD200 in patients age 6-12 years with ADHD using a classroom study design.

Timeline

Start
2014-05
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HLD200 Unknown 20 mg Oral
Subject HLD200 Unknown 40 mg Oral
Subject HLD200 Unknown 60 mg Oral
Subject HLD200 Unknown 80 mg Oral
Subject HLD200 Unknown 100 mg Oral

Indications

attention deficit-hyperactivity disorder